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Abstract
Cannabis is commonly used in cyclic vomiting syndrome (CVS) due to its antiemetic 
and anxiolytic properties. Paradoxically, chronic cannabis use in the context of cyclic 
vomiting has led to the recognition of a putative new disorder called cannabinoid hy‐
peremesis syndrome (CHS). Since its first description in 2004, numerous case series 
and	case	reports	have	emerged	describing	this	phenomenon.	Although	not	pathog‐
nomonic, a patient behavior called “compulsive hot water bathing” has been associ‐
ated with CHS. There is considerable controversy about how CHS is defined. Most of 
the data remain heterogenous with limited follow‐up, making it difficult to ascertain 
whether chronic cannabis use is causal, merely a clinical association with CVS, or 
unmasks or triggers symptoms in patients inherently predisposed to develop CVS. 
This article will discuss the role of cannabis in the regulation of nausea and vomiting, 
specifically focusing on both CVS and CHS, in order to address controversies in this 
context. To this objective, we have collated and analyzed published case series and 
case reports on CHS in order to determine the number of reported cases that meet 
current Rome IV criteria for CHS. We have also identified limitations in the existing 
diagnostic framework and propose revised criteria to diagnose CHS. Future research 
in this area should improve our understanding of the role of cannabis use in cyclic 
vomiting and help us better understand and manage this disorder.
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1  | INTRODUC TION
Cyclic vomiting syndrome (CVS) is a chronic functional gastrointes‐
tinal disorder that is characterized by recurrent episodes of severe 
nausea and vomiting and is currently defined by Rome IV criteria.1 
Cannabinoid hyperemesis syndrome (CHS) shares many clinical fea‐
tures with CVS except for its association with chronic, heavy can‐
nabis	use.	CHS	was	 first	described	 in	2004	by	Allen	et	al2 in nine 
patients. This report was followed by several case series and indi‐
vidual case reports describing a similar pattern of episodic nausea 
and severe vomiting referred to as “hyperemesis.”3,4 Heavy cannabis 
use preceded the onset of symptoms in these patients, suggesting 
that	chronic	cannabis	use	leads	to	hyperemesis.	A	diagnostic	frame‐
work for CHS was proposed, although there has been considerable 
variation in the diagnostic criteria used in the literature to define 
cases. This heterogeneity has led to significant controversy and un‐
certainty about CHS as a distinct entity.
The diagnosis of CHS is now made using Rome IV criteria which 
include stereotypical episodic vomiting resembling CVS occurring 
after prolonged, excessive cannabis use (Table 1). Notably, the cri‐
teria included cessation of vomiting episodes following sustained 
abstinence from cannabis to make this diagnosis, although it lacked 
more specific details about the duration required for symptom res‐
olution. The pathological phenomenon of “hot water bathing” was a 
supporting criterion even though this behavior can also be seen in 
~50%	of	patients	with	CVS	who	do	not	use	cannabis.	We	discuss	the	
strengths and limitations of the Rome IV framework for diagnosis 
and propose revised criteria for CHS in this article.
The prevalence of CHS in adults remains uncertain and is in large 
part	due	to	the	lack	of	consistent	diagnostic	criteria.	A	recent	pop‐
ulation‐based study identified only seven cases of CHS when the 
newer Rome IV diagnostic criteria were applied.5 In stark contrast, 
another study reported that nearly a third of daily or near‐daily 
cannabis users presenting to the emergency department were iden‐
tified as having CHS.6	A	major	flaw	in	this	particular	study	was	that	
the authors defined CHS primarily on the reported use of hot show‐
ers/baths to relieve symptoms of nausea and vomiting. There were 
no data on the frequency of hot showers, frequency of vomiting, or 
even whether the vomiting was episodic in nature, which is a defin‐
ing characteristic for both CVS and CHS. Previous studies clearly 
demonstrate that the “compulsive hot water bathing” pattern that 
frequently accompanies CHS is also commonly seen in adult patients 
with CVS who do not have cannabis use, as well as in those with 
chronic nausea and vomiting.7,8 Thus, it is unlikely that all patients 
described in the study by Habboushe et al had CHS, and more rig‐
orous criteria are needed to determine the true prevalence of CHS.
Gaps in knowledge about the basic features of CHS and the rela‐
tionship of chronic cannabis use with cyclic vomiting require atten‐
tion especially in light of the varied perceptions and beliefs of the 
risks and benefits of cannabis use. In addition, the concerted medical 
and recreational movements for cannabis liberalization and legaliza‐
tion will likely increase cannabis use in the future.9,10 In this article, 
we will discuss the role of cannabis and the endocannabinoid system 
(ECS) in the regulation of nausea and vomiting, as it pertains to both 
CVS and CHS. We will then present an overview of the published 
Key Points
• Cannabinoid hyperemesis syndrome (CHS) presents 
with cyclical emetic episodes mimicking cyclic vomiting 
syndrome after long‐standing cannabis use, often with 
associated pathologic bathing behaviors and is currently 
diagnosed with Rome IV criteria.
•	 A	systematic	review	of	the	literature	on	CHS	shows	sig‐
nificant limitations due to incompletely characterized 
case series and individual cases, especially with regard 
to follow‐up, and variable diagnostic criteria which pre‐
ceded development of Rome IV criteria.
• The limitations of the Rome IV criteria are discussed 
with proposed revisions to optimize future diagnosis of 
CHS.
• Future research in CHS focused on pathophysiology, 
clinical presentation and natural history is needed to 
ascertain whether CHS is a distinct entity or a subset of 
CVS.
TA B L E  1   Rome IV criteria for cannabinoid hyperemesis 
syndrome
Stereotypical episodic vomiting resembling (CVS) in terms of onset, 
duration, and frequency
Presentation after prolonged, excessive cannabis use
Relief of vomiting episodes by sustained cessation of cannabis use
Supportive remarks:
 May be associated with pathologic bathing behavior (prolonged hot 
baths or showers).
Note: Criteria fulfilled for the last 3 months, symptom onset at least 
6 months before diagnosis.
College of Wisconsin, Milwaukee, WI.
Email: tvenkate@mcw.edu
Funding information Funds for this work 
were provided by the Cyclic Vomiting 
Syndrome	Association	(CVSA).
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literature on CHS and use this data to challenge the current concept 
that CHS is distinct from CVS. We also propose new strategies to 
enhance our understanding of CHS, and address controversies and 
knowledge gaps that exist.
2  | EFFEC TS OF C ANNABINOIDS IN THE 
REGUL ATION OF NAUSE A AND VOMITING
Cannabis has been used as medicine dating back to the Neolithic 
period. It has been recently used to alleviate multiple symptoms in‐
cluding nausea, vomiting, and pain, as well as for treating refractory 
seizures.11‐13 The mechanism of action of cannabis was not well un‐
derstood until the early 1990s when the ECS was discovered.14 The 
ECS consists of two primary endogenous ligands, N‐arachidonoyle‐
thanolamine	(anandamide,	AEA)	and	2-arachidonoylglycerol	(2-AG),	
their receptors, and degrading enzymes. The cannabinoid receptors 
consist of the cannabinoid receptor type 1 (CB1R) and cannabinoid 
receptor type 2 (CB2R).15 These receptors are distributed in both the 
central and the peripheral nervous systems and are present on pre‐
synaptic nerve terminals of both inhibitory and excitatory neurons.16 
Endogenous ligands are synthesized on demand during periods of 
stress and are important in the regulation and attenuation of nausea, 
vomiting,	and	stress.	AEA	is	degraded	by	fatty	acid	amide	hydrolase	
(FAAH),	and	2-AG	is	degraded	by	monoacylglycerol	lipase	(MAG-li‐
pase).179‐tetrahydrocannabinol (THC), the major psychoactive ingre‐
dient in cannabis, exerts its effects primarily by acting on CB1R. 14,16
Several preclinical and human studies indicate that cannabinoid 
receptor agonists (phytocannabinoids [ie, cannabis] and endocan‐
nabinoids [ECs]) inhibit peripherally and centrally initiated emesis 
through their actions on CB1R.18,19 CB1Rs are densely distributed 
in areas of the brain such as the dorsal vagal complex, which is a 
critical part of the neurocircuitry that generates emesis.20 Further, 
CB1R antagonists can initiate or worsen emesis.21 The role of CB2R 
in nausea and vomiting is less clear. Studies of emesis in animals are 
particularly challenging as commonly used laboratory species such 
as rats and mice do not vomit. Thus, other species which do vomit, 
such as ferrets and shrews, are often used. However, most rodents 
exhibit “gaping” behaviors that appear to be induced by nauseogenic 
stimuli, and these behaviors are accepted surrogate markers for nau‐
sea.229-tetrahydrocannabinolic	acid	(THCA),	a	precursor	of	THC,	re‐
duced lithium chloride‐induced emesis in the musk shrew and also 
reduced “conditioned gaping” in rats.23 This effect was reversed by 
administration of rimonabant, a CB1R antagonist. In contrast to hu‐
mans, there were no psychoactive effects in rhesus monkeys with 
administration	of	THC	up	to	5	mg/kg,	demonstrating	different	dose	
responses that produce anti‐emetic effects vs psychomotor impair‐
ment among different species.19
Human studies also indicate that the ECS is involved in mediat‐
ing	nausea	and	vomiting.	A	 study	by	Chouker	et	 al24 showed that 
subjects who were prone to motion sickness had lower endocan‐
nabinoid	 levels	 and	 reduced	CB1R	mRNA	expression	during	 simu‐
lated parabolic flight compared to those who did not have motion 
sickness. This suggests that a relative EC deficiency may be asso‐
ciated with disorders of nausea and vomiting and thus, conversely, 
augmenting ECs may be useful in relief of vomiting.24 Following this, 
a	 study	 of	 the	 ECS	 and	 the	 hypothalamic-pituitary-adrenal	 (HPA)	
axis in CVS revealed an increase in EC levels during the emetic phase 
of the illness compared to the interepisodic phase.25 However, how 
this increase in ECs compares to the response in normal subjects 
exposed to emetic stimuli remains to be determined; also, the same 
study showed an increase in salivary cortisol in CVS patients who 
used cannabis compared to non‐users.25 Whether this increase in 
salivary cortisol in cannabis users represents an adaptive or mal‐
adaptive response is unclear.
Taken together, these and other findings indicate that canna‐
binoid receptor agonists inhibit vomiting and that CB1 receptor 
antagonists initiate or potentiate vomiting. Thus, the ECS is well po‐
sitioned to play a major role in both CVS and CHS. We speculate that 
the paradoxical effects of chronic cannabis may be caused by differ‐
ential degrees of CB1R downregulation in genetically predisposed 
individuals. This potential mechanism is supported by studies in rats 
which show that CB1R downregulation occurs after prolonged and 
repeated exposure to cannabis inducing tolerance to its effects.26 
Postmortem studies in humans also demonstrate CB1R downregula‐
tion in the human brain with chronic cannabis use compared to non‐
users.27 Other reasons for the paradoxical emetic effects of chronic 
cannabis use could be the result of increasing potency of cannabis 
(with higher ratios of THC to cannabidiol) and prolonged duration 
of use. It is likely that cannabis has a biphasic mechanism of action, 
where it has anti‐emetic effects at lower or less frequent dosing but 
is	pro-emetic	at	higher	or	more	sustained	doses.	Additionally,	can‐
nabis also has peripheral effects and affects gastric motility in both 
animal and clinical models. Δ9‐tetrahydrocannabinol reduced rates 
of gastric emptying in mice and rats and caused a significant delay 
in gastric motility when administered to healthy volunteers, which 
may contribute to episodes of hyperemesis.28,29 These findings are 
of clinical importance and must be considered if gastric emptying 
studies are performed in patients with disorders of cyclic vomiting 
who use cannabis.
3  | C ANNABIS USE IN C VS AND CHS
Although	 cannabis	 is	 the	 most	 commonly	 used	 illicit	 drug	 in	 the	
United States,30 the growing movement in support of cannabis use 
has led its legalization for medical purposes in 30 states and for rec‐
reational use in 10 states and the District of Columbia. Therefore, an 
increasing number of adolescents and adults are routinely exposed 
to cannabis in the United States. Though cannabis has >200 con‐
stituents,	its	psychotropic	effects	are	primarily	due	to	THC.	Another	
compound found in cannabis, cannabidiol (CBD), also has acute 
antiemetic effects but does not share the psychotropic effects of 
THC.31‐34 Cannabis preparations commonly used for recreational 
use contain increasing amounts of THC (relative to CBD content), 
and these changes in THC:CBD ratio are thought to account for 
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the increasing toxicity associated with its use.35,36 While cannabis 
preparations have been used for purported medical benefits as anti‐
emetics, recent reports have linked its use with CHS.3,10,37,38 CHS is 
now defined by Rome IV criteria shown in Table 1.1
There are ample data showing that many CVS patients resort 
to	 alternative	 therapies	 like	 cannabis	 to	 treat	 their	 symptoms.	 A	
study of 82 patients with CVS and functional vomiting showed that 
the use of cannabis was significantly higher in CVS (OR = 2.9 [1.2, 
7.2],	P = 0.02), compared to those with functional vomiting.8	 An	
Internet-based	 study	of	514	patients	with	CVS	 showed	 that	81%	
used cannabis for its therapeutic potential.7	A	more	recent	study	
(unpublished data) used validated tools in a large cohort of CVS 
patients to characterize cannabis‐use patterns and to ascertain 
the proportion of CVS patients who could be reclassified as having 
CHS based on recent Rome IV criteria.39	Of	140	respondents,	41%	
were	current	cannabis	users	and	21%	were	regular	users	(defined	
as	those	using	cannabis	≥	24	times	a	week	over	the	prior	6	months).	
Among	all	cannabis	users,	88%	reported	abstaining	from	cannabis	
for at least one month, but only one user in this study reported 
subsequent resolution of CVS episodes. However, this particular 
patient subsequently resumed using cannabis and remains symp‐
tom‐free.39	Among	this	cohort,	none	of	the	patients	met	Rome	IV	
criteria for CHS. This could be because the duration of abstinence 
from cannabis required for resolution of symptoms is greater than 
a month, and long‐term studies will be needed to clarify this ques‐
tion. The absence of potential CHS cases in a well‐characterized 
CVS cohort, when combined with the described case reports of 
CHS, raises important questions that warrant further investigation. 
For example: Why does cannabis relieve vomiting in some patients 
but exacerbate it in others? Is this phenomenon dose‐related, due 
to a specific genetic predisposition or both? Does cannabis use 
drive a distinct emetic disorder, or does it trigger CVS attacks, thus 
representing a subset of CVS? It is possible that previously diag‐
nosed cases of CHS are overestimates, and more systematic study 
will reveal the true prevalence of CHS.
4  | HE ALTHC ARE UTILIZ ATION FOR 
CYCLIC VOMITING FOLLOWING C ANNABIS 
LEGALIZ ATION
With a growing interest in the use of cannabis for medical pur‐
poses, several studies have focused on healthcare utilization as‐
sociated with cannabis use. In a retrospective cross‐sectional study 
of ED visits in Colorado, there was nearly a doubling of the re‐
ported rate of cyclic vomiting cases in the year following marijuana 
legalization compared to the year prior.40 However, the absolute 
number of cases in the postlegalization period was fairly low with 
a	 reported	 cyclic	 vomiting	 rate	 of	 ~0.07%	 of	 all	 ED	 visits.	 Using	
different methodology, a retrospective single‐center study found 
that	 the	presence	of	 cannabis	abuse	was	associated	with	a	~1.5-
fold increase in median ED visits per year for vomiting, compared 
to those without cannabis abuse.41 Finally, another study using 
the National Emergency Department Sample found that the rate 
of ED visits for vomiting among those with cannabis‐use disorder 
increased	more	than	~5.5-fold	between	2006	and	2013,	reaching	
an absolute prevalence of ~13 per 100 000 ED visits. During this 
period, the individual ED visit costs were found to have increased 
70%	and	 the	 total	 aggregate	 costs	 for	ED	visits	with	 vomiting	 in	
those with cannabis‐use disorder in 2013 was about $83 million.42 
Clearly, there is some indication that the more widespread use of 
cannabis in the population has increased the number of cannabis‐
related cyclic vomiting episodes over time, even though the overall 
prevalence of cyclic vomiting among those regular cannabis users is 
fairly low. There also remains a possibility that the initial reports of 
CHS instigated more directed queries about cannabis use in adults 
who present to EDs with vomiting, leading to an apparent increase 
in related cases due to an ascertainment bias.
5  | CHS: SYSTEMATIC RE VIE W
5.1 | Methods
We conducted a review of all cases diagnosed with CHS from January 
2000 to March 2018. The objective of our study was to identify all 
articles relevant to the diagnosis of CHS and to determine what pro‐
portion of previously reported CHS patients would meet current 
Rome IV criteria for CHS. We obtained articles used in the original 
literature	 search	 by	Monte	 et	 al	 using	MEDLINE,	Ovid	MEDLINE,	
Embase,	Web	of	 Science,	 and	 the	Cochrane	 Library	 from	 January	
2000	 through	 September	 24,	 2015.43 Search terms included can‐
nabinoids, cannabis, marijuana abuse, medical marijuana, tetrahy‐
drocannabinol, hyperemesis, emesis, vomiting, cannabis addiction, 
medical cannabis and hyperemesis. This search had identified a total 
of	2178	articles,	of	which	183	articles	were	available	for	inclusion.
A	 second	 literature	 search	 was	 then	 repeated	 using	 the	 same	
search	terms	in	the	time	frame	of	September	25,	2015-March	2018	in	
order to capture additional articles that were published after the origi‐
nal	search	by	Monte	et	al.	A	total	of	864	abstracts	were	reviewed,	and	
articles relevant to the diagnosis of CHS were included. Those that 
primarily addressed treatment with capsaicin, duplicate articles, stud‐
ies published in non‐English journals, and those that were not relevant 
to CHS were excluded from analysis. Many patients in both the case 
series and individual reports had comorbid diagnoses that may have 
contributed to refractory nausea and vomiting, such as hyperemesis 
gravidarum, and these cases were also excluded. Patients presenting 
with only a single emetic episode or with attacks which could have 
been explained by other pathogenic factors were also excluded. The 
quality of the data was heterogenous with variations in diagnostic cri‐
teria, the reporting of cannabis use, and a specific follow‐up period.
We (author TV assisted by YP) performed data abstraction on all 
these CHS cases including demographic data, cannabis‐use patterns 
(duration and frequency of use), hot shower bathing patterns, and 
duration of follow‐up. We then applied Rome IV criteria to both case 
series and individual cases to determine the number of patients who 
actually met the current Rome IV criteria for CHS. Rome IV criteria 
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require “sustained cessation of cannabis use resulting in resolution 
of symptoms” to make a diagnosis of CHS. However, since the Rome 
IV criteria do not specify the minimum required duration for absti‐
nence from cannabis, we chose a minimum duration of at least a 
month (4 weeks) of abstinence from cannabis prior to the resolution 
of symptoms to make a diagnosis of CHS. This particular duration 
of time was chosen due to the prolonged 2‐ to 3‐month elimination 
period that results from the lipophilic storage of cannabis in the 
setting	of	chronic	use.	Although	this	represented	a	reasonable	min‐
imum length of time to demonstrate improvement or resolution of 
symptoms following abstinence, this duration of time may still be 
insufficient as even after THC is cleared, restoration of CB recep‐
tor function may take even longer. Thus, patients may need to be 
followed for a length of time that equals at minimum three typical 
cycles or a period of 6‐12 months to determine whether cannabis 
cessation truly results in durable resolution of symptoms.
6  | RESULTS
Our	 review	 of	 the	 literature	 identified	 a	 total	 of	 25	 case	 series	
(n	=	271)	and	105	individual	case	reports	of	patients	identified	with	
CHS (Table 2).2,4,44-171 Most of the reported case series and case 
studies predated the publication of Rome IV criteria for CHS. Not 
surprisingly, these earlier reports had significant heterogeneity 
in the criteria used to define CHS cases. Some authors diagnosed 
CHS when patients presented with cyclic vomiting in the context of 
chronic cannabis use. Others used cyclic vomiting with hot shower 
bathing patterns as pathognomonic features of CHS.
In	the	case	series	totaling	271	patients	(“case	series”),	the	mean	
age	was	30.5	±	7.6	years	and	the	majority	of	patients	were	male	(186;	
68.6%).	The	mean	duration	of	cannabis	use	preceding	onset	of	symp‐
toms	was	6.6	±	4.3	years.	Daily	cannabis	use	was	found	in	two-thirds	
(68%),	 and	 weekly	 cannabis	 use	 in	 about	 one-sixth	 (~16%)	 of	 pa‐
tients.	The	frequency	of	cannabis	use	was	not	documented	in	16%	of	
the sample. The compulsive hot water bathing pattern was noted in 
71.5%	(194)	of	patients,	with	data	not	available	in	four	patients.	The	
mean age of patients in individual case reports (“case reports”) was 
29.4	±	9	years,	and	these	individuals	were	similarly	composed	mostly	
of	males	 (72.3%).	Duration	of	cannabis	use	among	the	case	report	
group	was	8.0	±	8.4	years,	and	daily	cannabis	use	was	reported	in	
69.5%,	very	similar	to	the	case	series	group.	The	hot	water	bathing	
pattern	in	the	case	report	group	was	noted	to	be	~	86%.
Among	the	case	series	and	individual	case	reports,	only	44/271	
(16.2%)	and	27/105	(25.7%)	respectively	had	a	follow-up	period	of	at	
least	≥4	weeks.	This	precluded	making	a	definite	diagnosis	of	CHS	
(using Rome IV criteria) in the vast majority of cases series and case 
reports due to such inadequate follow‐up. However, among those 
in	both	groups	who	were	followed	for	at	least	4	weeks,	86%	of	case	
series	patients	(38/44)	and	78%	of	case	report	patients	(21/27)	with	
a	total	of	59/71(83%)	met	Rome	IV	criteria	for	CHS.	Among	all	376	
cases,	only	59	 (15.7%)	or	approximately	1/6	of	the	cases	of	“CHS”	
reported in the literature met the Rome IV criteria for CHS.
In summary, the case series provided fewer clinical details on the 
patients with proposed CHS than did the individual patient reports. 
This was particularly evident in the larger series by Simonetto et al 
(98 patients) and Schreck et al (29 patients), in which details regard‐
ing cannabis cessation were difficult to extract.4,164 Follow‐up of pa‐
tients following abstinence from cannabis was also missing in most 
of the case series and case reports, a major limitation that questions 
the validity of the diagnosis of CHS in many of these cases. Future 
reports describing CHS should include greater rigor in characteriz‐
ing symptom improvement or resolution with prolonged and doc‐
umented (eg, toxicology screening for THC) cannabis abstinence to 
better understand the disorder and to avoid inappropriately invoking 
this diagnosis when other conditions may be causative of symptoms.
In general, the low numbers of patients who fulfilled Rome IV cri‐
teria for CHS in the reported case series and reports resulted largely 
from inadequate outcome data and length of follow‐up. These long‐
term outcomes data were not systematically captured in previous 
studies due to the lack of overall diagnostic framework and were 
admittedly difficult to capture in acute care settings. This likely led 
to an overestimate of CHS. Transitioning to a more nuanced and de‐
fined diagnostic framework will enable a better understanding of the 
association between cannabis and CHS.
7  | DIAGNOSIS OF CHS
The diagnostic criteria used for CHS have been heterogenous lead‐
ing to significant confusion about what constitutes CHS and even 
whether it a separate entity. While the Rome IV criteria lay a frame-
work for making a diagnosis of CHS, it has limitations and thus warrants 
iterative revision. The CVS Guidelines Committee proposes a revised set 
of criteria to optimize the diagnostic accuracy of CHS. Our proposed 
revised criteria are shown below in Table 3. There was consensus 
among the majority of committee members regarding the proposed 
revised criteria. These criteria provide more specific details regard‐
ing patterns of cannabis use and in particular the duration of follow‐
up required for establishing the diagnosis, which are not adequately 
specified in the Rome IV criteria. Our proposed criteria were de‐
veloped following a review of the available literature, properties of 
cannabis and our cumulative knowledge of purported CHS. Both the 
case series and individual case reports support our proposed revised 
criteria.
Cyclic vomiting episodes following chronic cannabis use are re‐
quired for a diagnosis of CHS. In contrast to Rome IV, we have spec‐
ified that at minimum, cannabis use of >4 times/week for at least 
a year preceding the onset of cyclic vomiting is necessary for the 
development of CHS. This is supported by current literature show‐
ing that prolonged, high‐dose cannabis use precedes development 
of CHS in the majority of described cases. Most patients in both the 
case series and case reports reported daily cannabis use for more 
than a year. Patients using <4 times/week are “occasional cannabis 
users” and should not be considered to have CHS. Data describing 
amounts, potency, and routes of cannabis used were less complete, 
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and we propose that future data collection be standardized and 
comprehensive with details regarding cannabis use (Table 4). This 
will be important as there may exist thresholds for cannabis use (ie, 
by duration, route, frequency of use, and/or dosing), which can lead 
to hyperemesis in individual patients.
Other important considerations included length of follow‐up 
after abstinence from cannabis. Ongoing evaluation in an outpa‐
tient setting to assess response to abstinence from cannabis, prior 
to making a diagnosis of CHS is critical given the episodic nature of 
the illness. For example, a patient who experienced 3 cycles/year 
while regularly using cannabis would need to be followed for at least 
one year after abstinence from cannabis to establish a diagnosis of 
CHS. Similarly, a patient with an episode every 6 weeks would need 
to	be	 followed	for	~4-5	months	after	cannabis	cessation.	Because	
CHS and CVS both consist of self‐limiting episodes of emesis, it is 
crucial that the clinician who encounters a patient with possible CHS 
recognizes the need to establish causality prior to ascribing this di‐
agnosis. The exact length of time that one would need to abstain 
from cannabis before resolution/reduction of CVS episodes occurs 
is not known as this will likely depend on the duration, quantity, and 
potency of cannabis use and genetic factors that could influence the 
response to cannabis use in individual patients.172,173
We acknowledge that maintaining complete abstinence from 
cannabis can be a challenge given patient perceptions and beliefs 
about	cannabis	use	and	its	potential	therapeutic	benefits.	A	limita‐
tion of both the Rome IV criteria and our proposed criteria is the 
challenge with patients who cannot or are reluctant to stop cannabis 
due to perceived benefits. In this instance, careful consideration of 
the quantity of cannabis used (daily vs occasional use) and screen‐
ing	for	cannabis-use	disorder	should	be	undertaken.	A	presumptive	
diagnosis of CHS may be considered when chronic (>1 year), daily 
use is encountered in the context of cyclic vomiting, and a failure to 
respond to standard prophylactic agents. Treatment for CVS with 
TCAs	and	ongoing	care	by	an	experienced	team	with	counseling	to	
reduce	and	ultimately	stop	cannabis	use	is	recommended.	Avoiding	
a confrontational and judgmental approach and establishing a rap‐
port with the care team is crucial to achieving good patient care 
outcomes.
Future systematic studies on cannabis and its role in vomiting 
disorders like CVS and CHS should guide and inform recommenda‐
tions regarding its medicinal and recreational use. Several import‐
ant questions about the exact duration and amount of cannabis 
and genetic factors that predispose to hyperemesis are not known. 
Future studies involving patterns of cannabis use and genetic vari‐
ants which potentially cause or exacerbate vomiting should help us 
better understand this disorder. Such human studies are particularly 
important as animals such as rats and mice used in preclinical studies 
do not vomit, which makes research in this area challenging.
The diagnosis of CHS can not only be stigmatizing (akin to mi‐
graine sufferers mislabeled as acute opioid seekers) but has resulted 
in some providers withholding symptomatic care and potentially ef‐
fective therapies.174 The significant impact that this stigma has on 
individual patients, their families, and the entire healthcare system 
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cannot	be	overemphasized.	As	with	other	drugs	of	abuse	such	as	nic‐
otine, research and efforts on a national scale are needed to educate 
and inform the public to achieve better outcomes. This also under‐
scores the need for a multidisciplinary approach with incorporation 
of experts in mental health and substance abuse in the care team for 
this challenging group of patients.
8  | IS CHS A SEPAR ATE ENTIT Y?
8.1 | Epidemiology and clinical features
The striking similarities between CVS and CHS suggest that CHS 
may in fact represent a subset of CVS rather than being a distinct 
disease. To be considered separate conditions, CHS and CVS must 
affect different patient populations or exhibit differentiating clinical 
features, longitudinal courses, and/or responses to disease‐specific 
therapies which would benefit one but not the other condition. The 
pathogenic importance of cannabis as a cause or trigger of nausea 
and vomiting syndromes is supported by recent epidemiologic find‐
ings	showing	8%	yearly	increases	in	hospital	discharges	for	persistent	
vomiting after cannabis legalization compared to the prelegalization 
era.175 However, this may be due to a recognition bias, as the pattern 
of	cyclic	vomiting	was	not	recognized	by	>80%	of	the	time	by	(ED)	
physicians.176 Of note, the same study indicated that a treatment 
protocol for CVS was available to ED physicians only in a minority 
of cases. This underscores the importance of having a specific pro‐
tocol for management of CVS in an acute care setting, which can 
aid ED physicians streamline management of CVS in the future. It is 
possible that the liberalization and legalization of cannabis, with the 
concomitant media exposure, has inadvertently highlighted this pre‐
viously unrecognized pattern of cyclic vomiting, leading to increased 
recognition of this pattern diagnosed as CHS over the last decade.
Are	there	clinical	features	that	reliably	distinguish	CHS	from	CVS?	
Both disorders commonly affect young people. Overall, there is a 
male predominance to CHS, which reflects greater use of cannabis 
products among men. Some studies have shown that CVS is more 
common in women, but there have been mixed results regarding gen‐
der predilection.177-180	Abdominal	pain	is	considered	by	some	to	be	
essential for CHS diagnosis, but pain is also reported by a substan‐
tial proportion of patients with CVS.181 More significantly, CHS has 
been prominently linked to a pattern of hot bathing or showering to 
relieve symptoms. This unusual behavior has been included by some 
as a mandatory criterion for CHS diagnosis.4 One retrospective study 
commented that “the ability of hot water bathing and showering to 
TA B L E  4   Proposed data collection sheet for cannabinoid hyperemesis syndrome
1 Demographics
2 Vomiting episodes:
a  date of onset
b frequency of vomiting episodes over the previous 12 mo and since onset of symptoms
c duration of typical episode, presence of symptoms including headache abdominal pain
d hot water bathing patterns and symptomatic response
e duration of coexistent inter‐episodic quiescent intervals 
3 Cannabis use:
a duration of cannabis use preceding onset of symptoms
b frequency of cannabis use
c type and potency (when available) of cannabis products
d  routes of use (smoked, oral, vaping etc.) 
4 Comorbid conditions –
a anxiety
b depression
c panic
d migraine 
5 Prior treatment and efficacy
6 Follow‐up periods defined by absolute time (ie, at least 6 mo) or by a duration of time defined by patient cycle length (ie, at least three 
successive cycles in an individual patient).
7 Periods of abstinence measured by number of weeks and monitoring with urine toxicology screens when feasible 
TA B L E  3   Proposed new diagnostic criteria for cannabinoid hyperemesis syndrome (CHS)
Clinical features Stereotypical	episodic	vomiting	resembling	CVS	in	terms	of	onset,	and	frequency	≥3	episodes	a	year
Cannabis‐use patterns Duration of use >1 y preceding onset of symptoms 
Frequency of use >4 times a week on average
Cannabis cessation aResolution of symptoms should follow a period of cessation from cannabis for a minimum of 6 mo or at 
least equal to a duration that spans three typical cycles in an individual patient
Note: aPatients unwilling or unable to abstain from heavy cannabis use pose a diagnostic challenge and may be considered to have presumed CHS. 
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mitigate symptoms” is the most defining characteristic of CHS while 
a second small series commented that these behaviors are “pathog‐
nomonic” for CHS.6,182	However,	nearly	10%	of	CHS	patients	do	not	
report this behavior even in articles which claim hot bathing to be 
essential for diagnosis.4,43,174 The specificity of this behavior was re‐
jected	 in	a	 recent	comparison	study	 in	which	48%	of	CVS	patients	
with no cannabis use reported symptom relief with hot baths or 
showers	compared	to	72%	who	used	cannabis.7 This hot water bath‐
ing behavior has been observed in preadolescent children and adoles‐
cents	with	no	exposure	to	cannabis	(BUK	Li	and	D	Fleisher,	personal	
communication). Thus, although the majority of studies show that 
chronic cannabis use is significantly associated with hot water bath‐
ing, this association is not pathognomonic of cannabis use.5
Both CHS and CVS are characterized by episodes of severe nausea, 
vomiting, and often abdominal pain that are relentless and can often 
be debilitating. They are typically self‐limited in nature with or without 
supportive therapy. These and other similar clinical features support 
our hypothesis that CHS is a subset of CVS where chronic cannabis use 
either unmasks or propagates symptoms in individuals who are predis‐
posed to develop CVS. However, many reports of CHS include patients 
presenting for the first time with vomiting (often associated with other 
potential causes of emesis like pregnancy).45,170 Given the limited de‐
tails provided, these observations reflect primarily the inadequacies 
of the published reports. However, they also raise the possibility that 
chronic cannabis use can cause symptoms of nausea and vomiting that 
are not episodic in pattern, and thus would clearly be distinct from 
CVS. This possibility would need to be confirmed or refuted in future 
series, perhaps best addressed in a matched cohort study.
8.2 | Treatment options for CHS
It has been contended that patients with CHS do not respond to 
standard therapies used for CVS.183 One report determined that 
chronic cannabis users with CVS respond less often to prophylac‐
tic treatment with tricyclic antidepressants compared to those not 
on cannabis.184 However, no multivariate comparisons were per‐
formed, and other known confounding factors (use of opioids and 
associated psychiatric comorbidities) that are associated with poor 
responses	to	TCAs	were	not	considered.	Conversely,	another	case	
series of patients with CVS with high proportions of cannabis users 
reported	>80%	response	rates	to	tricyclic	medications.185 Moreover, 
Venkatesan et al in another series which applied multivariate re‐
gression analysis did not observe differences in response rates to 
standard	prophylactic	agents	like	TCAs	in	patients	with	CVS	based	
on cannabis use.181 Very little rigorous study has been devoted to 
use of prophylactic treatment of CHS, with no definitive indication 
that CHS requires a specific pharmacological approach distinct from 
that used for CVS prophylaxis. Based on these observations, we rec‐
ommend that patients with moderate‐to‐severe cyclic vomiting that 
use cannabis be offered the same prophylactic medical therapies of‐
fered to patients with CVS.
Limited	 responses	 to	 abortive	 antiemetic	 medications	 are	
often mentioned in articles on CHS, while others report excellent 
responses	to	parenteral	benzodiazepines	(GABAA agonists) such as 
lorazepam, the neuromodulator olanzapine, or the potent D2 antag‐
onist	haloperidol—an	agent	with	overlapping	pharmacology	to	many	
commonly used antiemetic including prochlorperazine and metoclo‐
pramide.164,183,186 Prior studies have proposed selective benefits of 
topical capsaicin treatments for acute CHS attacks, potentially act‐
ing in similar fashion as hot baths.162,187 182,187,188 However, similar 
treatments have not been employed for patients with CVS without 
cannabis exposure, so the specificity of these benefits for CHS is un‐
certain. Because of the paucity of investigations supporting or refut‐
ing the use of other CHS therapies, it is imperative that patients with 
possible CHS are not denied prescription of prophylactic or abortive 
treatments which benefit patients with CVS.
The treatment of CHS has focused on cannabis cessation lead‐
ing to resolution of symptoms. The most comprehensive series to 
date	by	Allen	et	al	followed	patients	for	more	than	2	years	and	given	
that duration we surmise that cannabis cessation did indeed result 
in resolution of vomiting episodes. However, many articles describe 
brief periods of abstinence from cannabis as short as a few days of 
hospitalization, which are not meaningful and challenge their valid‐
ity in support of a diagnosis of CHS. When more stringent criteria 
have been applied, very few patients with purported CHS report 
symptom reduction lasting more than 3 months and almost no pub‐
lications describe improvements for at least two typical cycles of 
episodic emesis. This highlights the limitation of the current CHS 
literature as there is an ascertainment bias and potential overat‐
tribution which could call into question the CHS diagnosis in some 
who have been told they have the condition. On the other hand, 
application of the Rome IV criteria could lead to an underestimate 
if follow‐up is inadequate or if patients are unwilling to stop can‐
nabis. Furthermore, symptom resolution following cessation of can‐
nabis could be confounded by unrelated spontaneous resolution of 
symptoms which would muddy the apparent causal interpretation. 
In children with CVS, after 4 years of illness, spontaneous resolution 
(ie,	off	medication)	occurs	in	50%.189	Although	continued	remission	
off medications has been described in adults, how often this occurs 
remains unknown due to the limited long‐term follow‐up data and 
persistent use of medication in adults with CVS.190 Future reports 
describing CHS should include greater rigor in characterizing symp‐
tom improvement with prolonged cannabis abstinence to avoid inap‐
propriately making this diagnosis.
9  | CONCLUSIONS
In summary, when the literature is taken as an aggregate, while there 
are some differences in the demographic profile (males vs female pre‐
dominance) there is considerable overlap in the acute presentations of 
CHS and CVS. Our review of the literature reinforces our proposal that 
CHS is a subset of CVS in which chronic cannabis use triggers symp‐
toms in patients who are genetically predisposed to develop CVS. 
Future studies should focus on standardized collection of data includ‐
ing cannabis‐use patterns and accurate phenotyping and genotyping 
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of patients with CVS and CHS. Specifically, the potency of cannabis 
used, and antecedent duration and frequency of use should be char‐
acterized to assess its impact. Patients with presumed CHS should 
be advised to abstain from cannabis and should receive ongoing care 
from a multidisciplinary team including mental‐health and substance‐
use experts. These patients should concomitantly be offered standard 
care with prophylactic and abortive therapy similar to patients with 
CVS. This is critical given the gaps in our knowledge about the patho‐
physiology, diagnosis and management of CHS and the stigma that is 
associated with such a disorder. Future studies should also focus on 
elucidating the underlying pathophysiology such as the role of the 
ECS	and	the	HPA	axis	in	both	CVS	and	CHS.	This	should	advance	our	
knowledge in this area and help in the development of novel and tar‐
geted therapies. Government and industry‐sponsored funding along 
with participation from patient advocacy groups such as the Cyclic 
Vomiting	Syndrome	Association	(CVSA)	are	vital	to	achieve	our	goals	
of better understanding and treating this debilitating disorder.
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